Targepeutics is presenting the latest efficacy data related to treatment of GBM and DMG tumors with the novel immunotoxin, GB13. This data is presented as a poster presentation during the 28th Annual Meeting for the Society of NeuroOncology, being held in Vancouver, BC from November 15-19.
Dr Randy Schrecengost, Chief Scientific Officer, will present the poster entitled “GB13 is a potent treatment for IL13Rα2-expressing GBM and DMG and improves standard-of-care therapy” during the Friday evening poster session. Key highlights from the data demonstrate that convection enhanced delivery (CED) is a viable drug delivery mechanism for GB13 to significantly reduce tumor volume and increase survival. Excitingly, GB13 pretreatment substantially increases radiation-induced cell death and dramatically improved survival outcomes, compared to single agent conditions.
Details for the presentation:
Title: GB13 is a potent treatment for IL13Rα2-expressing GBM and DMG and improves standard-of-care therapy
Presenter: Randy Schrecengost, PhD, Targepeutics CSO
Abstract number: EXTH-54